Trials / Unknown
UnknownNCT05775575
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
A Phase Ib/II Study to Investigate the Safety, Tolerance and Pharmacokinetics of TQB3909 With HR-positive, HER2-negative Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB3909 is an inhibitor targeting B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3/7 activity and caspase 3/9 cleavage, and induces apoptosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3909 tablets | TQB3909 is an inhibitor targeting BCL-2 protein |
Timeline
- Start date
- 2023-03-02
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2023-03-20
- Last updated
- 2023-03-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05775575. Inclusion in this directory is not an endorsement.